Publications

2022

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. CNS Drugs. 2022 Dec; 2022 Nov 9. PMID: 36350491.
Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.Daboul L, O'Donnell CM, Cao Q, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree BAC, Freeman L, Henry RG, Longbrake EE, Nakamura K, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Suthiphosuwan S, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Ontaneda D, Sati P. AJR Am J Roentgenol. 2022 Nov 2; 2022 Nov 2. PMID: 35975888.
Toward Precision Phenotyping of Multiple Sclerosis.Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Neurol Neuroimmunol Neuroinflamm. 2022 Nov; 2022 Aug 30. PMID: 36041861.
Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion in multiple sclerosis.Asashima H, Axisa PP, Pham THG, Longbrake EE, Ruff WE, Lele N, Cohen I, Raddassi K, Sumida TS, Hafler DA. J Clin Invest. 2022 Oct 17; 2022 Oct 17. PMID: 36250467.
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic.Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, De Jager PL, Venkatesh S, Walker ELS, Xia Z, Weinstock-Guttman B. Mult Scler Relat Disord. 2022 Oct 9; 2022 Oct 9. PMID: 36283322.
Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis: A Case-Control Cross-sectional and Longitudinal Analysis.Riley CS, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit EE, Perrone C, Weinstock-Guttman B, Longbrake EE, De Jager PL, Xia Z. medRxiv. 2022 Sep 26; 2022 Sep 26. PMID: 36203554.
Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R. bioRxiv. 2022 Sep 2; 2022 Sep 2. PMID: 36093346.
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. Mult Scler Relat Disord. 2022 Aug 22; 2022 Aug 22. PMID: 36031693.
Myelin Oligodendrocyte Glycoprotein-Associated Disorders.Longbrake E. Continuum (Minneap Minn). 2022 Aug 1. PMID: 35938661.
The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders.Huang YT, Giacomini PS, Massie R, Venkateswaran S, Trudelle AM, Fadda G, Sharifian-Dorche M, Boudjani H, Poliquin-Lasnier L, Airas L, Saveriano AW, Ziller MG, Miller E, Martinez-Rios C, Wilson N, Davila J, Rush C, Longbrake EE, Longoni G, Macaron G, Bernard G, Tampieri D, Antel J, Brais B, La Piana R. Front Neurol. 2022; 2022 Jul 25. PMID: 35959404.
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications.Levit E, Longbrake EE, Stoll SS. Mult Scler Relat Disord. 2022 Apr; 2022 Mar 3. PMID: 35276450.
Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic.Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE. Mult Scler Relat Disord. 2022 Feb; 2022 Jan 4. PMID: 35016114.
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF. Mult Scler Relat Disord. 2022 Jan; 2021 Dec 2. PMID: 34923427.

2021

A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. Neurol Neuroimmunol Neuroinflamm. 2021 Sep; 2021 Aug 2. PMID: 34341094.
(23)Na imaging: Worth its salt for understanding multiple sclerosis.Longbrake EE, Hafler DA. Proc Natl Acad Sci U S A. 2021 Aug 17. PMID: 34376559.
Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure.Yu AW, Pecsok M, Longbrake EE, Wesley SF. Neurol Clin Pract. 2021 Aug. PMID: 34484946.
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Neurol Clin Pract. 2021 Aug. PMID: 34484933.
Influence of immunomodulatory drugs on the gut microbiota.Cohen I, Ruff WE, Longbrake EE. Transl Res. 2021 Jul; 2021 Jan 27. PMID: 33515779.
MOG-associated encephalitis following SARS-COV-2 infection.Peters J, Alhasan S, Vogels CBF, Grubaugh ND, Farhadian S, Longbrake EE. Mult Scler Relat Disord. 2021 May; 2021 Feb 23. PMID: 33647592.
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Mult Scler. 2021 May; 2020 Jul 27. PMID: 32716690.
The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events: Inducing or "Unmasking" Autoimmunity?Gardin T, Longbrake EE. Neurology. 2021 Apr 20; 2021 Mar 16. PMID: 33727404.
Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss-Farber R, Vargas WS, Banwell B, Bar-Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock-Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL. Ann Clin Transl Neurol. 2021 Apr; 2021 Feb 22. PMID: 33616290.

2020

Therapeutic considerations in a case of progressive encephalomyelitis with rigidity and myoclonus.Gluck L, Hernandez AL, Wesley SF, Fulbright RK, Longbrake EE, Stathopoulos P. J Neurol Sci. 2020 Sep 15; 2020 Jun 18. PMID: 32593886.
Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees.Hua LH, Obeidat AZ, Longbrake EE. Mult Scler Relat Disord. 2020 Sep; 2020 Jun 10. PMID: 32585616.
Sex effects across the lifespan in women with multiple sclerosis.Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A, Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M, Hellwig K. Ther Adv Neurol Disord. 2020; 2020 Jul 1. PMID: 32655689.
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.Obeidat AZ, Jassam YN, Hua LH, Cutter G, Ford CC, Halper J, Lisak RP, Sicotte NL, Longbrake EE. Neurology. 2020 Mar 17; 2020 Feb 27. PMID: 32107321.
CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome.Choileáin SN, Kleinewietfeld M, Raddassi K, Hafler DA, Ruff WE, Longbrake EE. J Transl Autoimmun. 2020; 2019 Dec 20. PMID: 32743517.

2019

Siponimod Chips Away at Progressive MS.Longbrake EE, Hafler DA. Cell. 2019 Dec 12; 2019 Dec 12. PMID: 31951523.

2018

Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Mult Scler. 2018 Sep; 2017 Aug 2. PMID: 28766993.
Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L. Mult Scler. 2018 May; 2017 May 8. PMID: 28480794.
Effectiveness of alternative dose fingolimod for multiple sclerosis.Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Neurol Clin Pract. 2018 Apr. PMID: 29708225.
A Neurology Clerkship Curriculum Using Video-Based Lectures and Just-in-Time Teaching (JiTT).Dominguez M, DiCapua D, Leydon G, Loomis C, Longbrake EE, Schaefer SM, Becker KP, Detyniecki K, Gottschalk C, Salardini A, Encandela JA, Moeller JJ. MedEdPORTAL. 2018 Mar 16; 2018 Mar 16. PMID: 30800891.

2016

Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.Longbrake EE, Lancia S, Tutlam N, Trinkaus K, Naismith RT. Mult Scler Relat Disord. 2016 Nov; 2016 Nov 4. PMID: 27919490.
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. Neurology. 2016 Sep 27; 2016 Aug 31. PMID: 27581217.
Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy Grail.Longbrake EE, Hafler DA. JAMA Neurol. 2016 Jul 1. PMID: 27244583.
An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.Wu GF, Longbrake EE. Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 2016 Apr 7. PMID: 27110589.
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity.Longbrake EE, Cross AH. JAMA Neurol. 2016 Feb. PMID: 26720195.
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Longbrake EE, Cross AH, Salter A. Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2016 Nov 1. PMID: 28280599.

2015

Dimethyl fumarate associated lymphopenia in clinical practice.Longbrake EE, Cross AH. Mult Scler. 2015 May; 2014 Nov 28. PMID: 25432948.
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Mult Scler J Exp Transl Clin. 2015 Jan-Dec; 2015 Jul 31. PMID: 26550483.